MAO-B-IN-39

MAO-B-IN-39 (compound11) is a selective monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-39 inhibits MAO-Bwith an IC50 of 3.61 μM. MAO-B-IN-39 demonstrates a potent NRF2 induction capacity. MAO-B-IN-39 exhibits potent anti-inflammatory and neuroprotective activity in OS (oxidative stress) -related in vitro models. MAO-B-IN-39 demonstrates high liver microsomal stability and favorable pharmacokinetics in mice. MAO-B-IN-39 is potential for Parkinson’s disease (PD) research[1].

Product Specifications

CAS Number

[3094045-97-0]

UNSPSC

12352005

Target

Keap1-Nrf2; Monoamine Oxidase

Related Pathways

Neuronal Signaling; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

O=C(NC1=CC=C2NC=CC2=C1)/C=C/C3=C(C=CC=C3)F

Molecular Formula

C17H13FN2O

Molecular Weight

280.30

References & Citations

[1]Zhang C, et al. Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors. ACS Med Chem Lett. 2025 Jan 22;16 (2) :301-310. |[2]Duarte P, et al. Network-Based Drug Optimization toward the Treatment of Parkinson's Disease: NRF2, MAO-B, Oxidative Stress, and Chronic Neuroinflammation. J Med Chem. 2025 Feb 13;68 (3) :3495-3517.